A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 7200 participants.

Also called NCT03984591

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 7,200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03984591
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT03984591. Randomized; no masking; primary purpose treatment. Start 2020-11-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
Acronym
CROWD-ASPECT
Condition
Systolic Heart Failure
Intervention (Drug)
Eplerenone
Intervention (Drug)
Spironolactone
Lead sponsor
Bispebjerg Hospital (class: other)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)

Record details

Record id
cardio:ct-nct03984591
Content hash
fc7aee21868ba226e5566a0aede8f6e28825ff44e4a582837023b7d5cf083b4c